Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
An apparent hit in Nash has more than doubled the group’s market cap. But are the data all they seem?
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.